Is BDX up or down today?
BDX is flat 0.03% today, last at 0.0768. This crypto moved -0.03% versus the prior close.
BDX · Beldex
Binance reconnecting · API fallback · List page updates every 30s
BDX (Beldex) is trading at 0.0768, flat 0.03% on the session. BDX carries a 14-day RSI of 34, and trades below its 50-day average. Over the past month it is down 5.94%.
Leading the coverage: “Becton, Dickinson and Company (BDX) Stock Analysis: Exploring a 5.91% Potential Upside in the Healthcare Giant - DirectorsTalk Interviews” (Google News Company, 5d ago). BDX is -2.10% since story.
BDX trades on a trailing P/E of 50.7 and is running 4.88% behind the S&P 500 over the same stretch.
Analyst firms are mostly reiterating — no strong directional shift lately.
BDX is flat 0.03% today, last at 0.0768. This crypto moved -0.03% versus the prior close.
Leading the coverage: “Becton, Dickinson and Company (BDX) Stock Analysis: Exploring a 5.91% Potential Upside in the Healthcare Giant - DirectorsTalk Interviews” (Google News Company, 5d ago). BDX is -2.10% since story. Dominant story: Becton Dickinson stock trades below analyst targets as investors weigh recent guidance - ad-hoc-news.de (1 source, bearish) RSI is 34 — leaning bearish Price below 50-day average — short-term weakness Social sentiment loads separately — see the Social tab.
Analyst firms are mostly reiterating — no strong directional shift lately.
Historical price chart unavailable
Live price streams via Binance WebSocket. OHLC history loads from Binance klines in your browser (USD · BTC/USDT). If Binance is unreachable, the chart stays blank rather than showing a mismatched curve.
Becton Dickinson stock trades below analyst targets as investors weigh recent guidance - ad-hoc-news.de
Becton Dickinson (BDX) Could Be 10% Undervalued As Dividend Lands - simplywall.st
Becton Dickinson stock gains on dividend and margin outlook - ad-hoc-news.de
BCAL Diagnostics (ASX:BDX) Shares Add 16.92% as Breast-Cancer Blood Test Story Draws Focus - Kalkine
Bcal Diagnostics (ASX:BDX) Shares Rise 14%, Avantect Test Access Expansion in Focus - Kalkine